Research programme: beta 3 adrenergic receptor agonists - Astellas Pharma

Drug Profile

Research programme: beta 3 adrenergic receptor agonists - Astellas Pharma

Alternative Names: β3 adrenergic receptor agonists - Astellas Pharma

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Benzoic acids; Biphenyl compounds; Small molecules
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Overactive bladder

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Overactive bladder in Japan (PO)
  • 10 Apr 2008 Preclinical trials in Overactive bladder in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top